877 results for "addiction"
Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review
Cureus – March 14, 2026
Summary
Esketamine shows promise as a dual-action treatment for patients with treatment-resistant depression (TRD) and comorbid substance use disorders (SUDs). With nearly 33% of major depressive disorder patients unresponsive to standard therapies, esketamine's efficacy in alleviating depressive symptoms is noteworthy. Studies indicate it may also reduce drug-seeking behavior and cravings, especially when paired with behavioral therapies. In rodent models, esketamine significantly decreased cocaine-seeking behavior, while clinical data suggest it could aid in alcohol misuse. Its potential as a comprehensive therapeutic approach warrants further exploration.
Abstract
Treatment-resistant depression (TRD) presents a complex clinical challenge, particularly when comorbid with substance use disorders (SUDs) or other...
Psilocybin or Nicotine Patch for Smoking Cessation
JAMA Network Open – March 10, 2026
Summary
Psychedelics show promise in reducing smoking behavior, with a significant 80% of participants achieving abstinence after a treatment involving psilocybin. In a sample of 15 individuals, those who received the psychedelic intervention reported markedly lower cravings and withdrawal symptoms compared to a control group. Additionally, assessments revealed that 67% maintained their smoke-free status six months post-treatment. These findings highlight the potential of psychedelics as innovative tools in smoking cessation efforts, offering new avenues for individuals struggling with addiction.
Abstract
ClinicalTrials.gov Identifier: NCT01943994.
The long roots of ibogaine: A journey from plant to pharmaceutical
Journal of Psychedelic Studies – March 09, 2026
Summary
Ibogaine's history reveals a complex interplay of colonialism and cultural appropriation, with significant implications for its role in modern medicine. Prior to the 1960s, ibogaine was commercialized in various products, including Dragées Nyrdahl and Ibobiose, highlighting its international diffusion. Notably, it was first used for substance use disorder treatment in Mexico in 1913, challenging dominant narratives. The analysis underscores the importance of indigenous knowledge in shaping scientific understanding, emphasizing the need to recognize the contributions of the Congo Basin communities in ibogaine's development and commercialization.
Abstract
Abstract Background and aims Ibogaine, one of the oldest psychedelic alkaloids introduced to Western society and medicine, has a largely overlooked...
Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings
Healthcare – March 03, 2026
Summary
Ketamine shows potential as a rapid treatment for acute suicidality, offering relief within hours compared to the 2-6 weeks required for traditional SSRIs. With suicide rates rising in the U.S., this is a crucial public health concern. A review of literature, including data from MEDLINE and PsycINFO, highlights that supervised subanesthetic doses of Ketamine pose low risks of addiction, distinguishing its therapeutic use. However, while promising, the proposed "Bridge Protocol" needs extensive validation through rigorous clinical trials before widespread adoption can occur.
Abstract
This narrative literature review explores the clinical use of Ketamine as part of an untested hypothetical model framework for bridge therapy for a...
Ketamine Therapy for Chronic Pain Provides Added Benefits for Substance Misuse Therapy
SVOA Medical Research – March 02, 2026
Summary
Chronic pain patients with substance misuse showed significant improvements after receiving monthly intramuscular ketamine treatments. In a cohort of 20 adults, 45% misused opioids, while others misused benzodiazepines (25%), cocaine (20%), and kratom (10%). Following treatment, mood scores improved from moderately severe to mild, pain levels decreased from severe to moderate, and dependence severity significantly lessened. This suggests that ketamine-based therapy could effectively address both chronic pain and substance misuse, enhancing patient outcomes and promoting public safety within healthcare systems.
Abstract
Background: Chronic pain is complicated by comorbid substance misuse. This multifaceted problem increases the risks of polypharmacy, overdose, impa...
Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention
Addiction Biology – March 01, 2026
Summary
Psilocybin and ibogaine show promise in reducing cocaine-seeking behavior in Wistar male rats. In a study involving 40 rats, psilocybin doses of 1.25 mg/kg and 5 mg/kg significantly decreased active lever pressing by 50% one day after the second dose. Ibogaine (10 mg/kg and 40 mg/kg) also demonstrated significant effects after the first administration. Notably, both compounds had no adverse effects on locomotor activity or anxiety levels. These findings highlight their potential roles in addiction treatment, particularly in facilitating extinction learning and possibly preventing relapse.
Abstract
Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Her...
Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind
Biomedicines – February 25, 2026
Summary
Ayahuasca, a traditional brew containing the powerful hallucinogen DMT, shows significant promise in treating treatment-resistant depression (TRD) and major depressive disorder (MDD). Current evidence highlights four phase II studies with 5-MeO-DMT and one with DMT for TRD, alongside two phase II trials with DMT fumarate for MDD. These compounds enhance neuroplasticity and reorganize brain networks linked to cognition and mood regulation. With growing interest in psychedelics, they not only offer therapeutic potential but also deepen our understanding of mental health and brain function.
Abstract
In recent years, psychopharmacology has experienced a significant challenge, highlighting a renewed and strong scientific interest in psychedelics ...
Opioid Receptors in Psychedelia: Indirect Serotonergic Modulation of Direct KOR Activation by Salvinorin A
Biomedicines – February 21, 2026
Summary
Salvinorin A, a potent compound from *Salvia divinorum*, uniquely activates the kappa opioid receptor (KOR), diverging from traditional serotonergic models. In studies involving over 100 human neuroimaging trials and various animal models, KOR activation was linked to significant alterations in consciousness and brain network fragmentation. Unlike classical psychedelics, salvinorin A's effects include rapid receptor desensitization and low abuse potential due to aversive experiences. This insight into the endogenous opioid system opens new avenues for treating conditions like addiction and chronic pain, highlighting diverse neurochemical pathways in psychedelics.
Abstract
The neuropharmacology of psychedelics has traditionally focused on serotonergic mechanisms, particularly 5-HT2A receptor activation. However, this ...
The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial
Addiction – February 16, 2026
Summary
Intravenous ketamine at a dose of 0.8 mg/kg significantly alters consciousness in individuals with alcohol use disorder. In a randomized controlled trial involving multiple infusions, participants consistently reported reduced alcohol consumption, suggesting a promising avenue for treatment. Notably, these reductions were not linked to the immediate psychoactive effects of ketamine. This highlights ketamine's potential as a novel intervention in addressing alcohol dependence and related psychiatric conditions, paving the way for innovative approaches in substance abuse treatment and outcomes.
Abstract
People with alcohol use disorder experience alterations in consciousness from 0.8 mg/kg intravenous ketamine administration. Ketamine's effects app...
Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD
OpenAlex – February 11, 2026
Summary
Greater mystical experiences during psilocybin treatment significantly reduce obsessive-compulsive disorder (OCD) symptoms. In a clinical trial with 27 participants, those reporting stronger mystical experiences showed lower OCD severity at both one and twelve weeks post-treatment. Specifically, the Mystical subscale of the experience questionnaire correlated most consistently with symptom reduction. This suggests that the quality of subjective experiences during psilocybin therapy may enhance treatment effectiveness, highlighting the importance of optimizing therapeutic conditions for improved outcomes in OCD management.
Abstract
Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have ...
Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders—A Scoping Review
Molecules – February 04, 2026
Summary
Addiction, particularly to opioids, leads to approximately 600,000 deaths each year globally. Current treatments for Substance Use Disorder (SUD) often focus on isolated neurobiological processes, resulting in high relapse rates. Ibogaine, an indole alkaloid from *Tabernanthe iboga*, shows promise due to its ability to target multiple pathways involved in addiction, potentially aiding in withdrawal and cravings. However, challenges such as safety concerns and inconsistent evidence hinder its clinical application. Continued investigation is essential for establishing safer and standardized therapeutic protocols.
Abstract
Substance Use Disorder (SUD) constitutes a major and persistent global public health burden, accounting for approximately 600,000 deaths annually, ...
Hippocampal subfield differences in people with and without recreational ketamine use: Insights from multi-modal neuroimaging.
Addiction (Abingdon, England) – January 29, 2026
Summary
Recreational ketamine use significantly impacts brain health. Among 58 individuals using ketamine and 73 tobacco users, heavier ketamine consumption correlated with greater psychological distress (r=0.343), anxiety (r=0.457), and hostility (r=0.442). Magnetic resonance imaging revealed reduced left hippocampus volume (η2=0.03), particularly in a specific hippocampal region (η2=0.08). Functional neuroimaging also showed altered connectivity, correlating with N‐methyl‐D‐aspartate receptor distributions (z=0.30). These changes accompany working memory impairments (η2=0.06), highlighting serious implications for substance‐related disorders.
Abstract
Recreational ketamine use has increased globally and is associated with psychiatric and cognitive concerns. The hippocampus in preclinical models s...
THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS
International Journal of Innovative Technologies in Social Science – January 23, 2026
Summary
A transformative shift in mental health treatment is emerging, moving beyond traditional monoaminergic medicine. Clinical trials reveal serotonergic hallucinogens like psilocybin and Lysergic Acid Diethylamide (LSD) offer rapid, episodic interventions for depression and addiction. These psychedelics impact the Default Mode Network, enhancing cognition. Psychotherapist-guided modalities facilitate transformative learning within psychiatry and psychology. This medicine's re-emergence necessitates comprehensive drug studies, including forensic toxicology and understanding how these powerful compounds influence pain management and transcend placebo effects.
Abstract
The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e....
Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias.
Addiction (Abingdon, England) – January 20, 2026
Summary
Ibogaine shows significant promise for addiction treatment, effectively reducing craving and withdrawal from opioid and cocaine dependence. However, this psychoactive compound and its metabolite, noribogaine, carry a rare but serious cardiovascular risk. It can cause QT interval prolongation and potentially fatal ventricular arrhythmias, even at therapeutic doses in healthy individuals. Variability in drug metabolism contributes to this danger. Future use demands strict medical supervision, personalized dosing, and rigorous cardiovascular monitoring, with safer ibogaine analogues showing promise.
Abstract
Revived interest in psychedelic-assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti-addictive pote...
Ibogaine for Opioid Use Disorder: An Unrecognized Risk
Journal of Addiction Medicine – January 15, 2026
Summary
Ibogaine has sparked interest as a potential treatment for opioid use disorder (OUD), with several states investing heavily in its exploration. However, switching from established medications like methadone or buprenorphine to ibogaine could pose serious risks; detoxification may lead to heightened overdose vulnerability. In a landscape where effective treatments are crucial—over 70% of OUD patients benefit from medication-assisted therapies—the addiction medicine community must prioritize evidence-based approaches while considering emerging options like ibogaine. Balancing innovation and safety is essential in tackling opioid-related disorders.
Abstract
The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid ...
Ibogaine for Opioid Use Disorder: An Unrecognized Risk.
Journal of addiction medicine – January 15, 2026
Summary
A critical safety concern arises as interest in ibogaine, a psychedelic, expands for opioid use disorder. Some proponents advocate for ibogaine as an alternative to established, life-saving medications like methadone and buprenorphine. Encouraging individuals to undergo detoxification and tapering off these proven therapies for an unvalidated treatment risks increasing overdose rates. While exploring new options, the medical community must steadfastly uphold evidence-based care, ensuring that the development of psychedelics like ibogaine complements, rather than undermines, current effective approaches to opioid use disorder.
Abstract
The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid ...
Traditional Knowledge and Therapeutic Application of Chiric Sanango (Brunfelsia grandiflora) in an Amazonian Rehabilitation Center.
Journal of psychoactive drugs – January 15, 2026
Summary
The psychoactive plant *Brunfelsia grandiflora*, or chiric sanango, significantly aids mental health and addiction treatment, according to an analysis of 74 patient case reports. Integrated as plant medicine within therapeutic diets, it fosters deep introspection and emotional processing. Patients frequently reported shifting from distressing emotions to states of clarity and resilience. While inducing physical sensations like numbness, chiric sanango enhances social engagement, underscoring its potential as an adjunct in addiction treatment and for overall psychological well-being.
Abstract
The use of traditional medicinal plants in therapeutic settings has gained increasing attention for their potential in mental health and addiction ...
Psychedelic Drugs Rediscovered-In Silico Study of Potential Fetal Exposure to Analogues of Psychedelic Drugs During Pregnancy.
Molecules (Basel, Switzerland) – January 08, 2026
Summary
A concerning finding reveals most of 250 psychedelic drugs and ketamine analogues readily cross the human placenta. A QSAR model, incorporating drug-likeness and other factors, identified specific atomic contributions: carbonyl and hydroxyl groups enhance placenta permeability, while bulky structures restrict it. The synthetic availability of these compounds makes them attractive for illicit manufacturing, underscoring the urgency for comprehensive pharmacological investigation into their potential effects.
Abstract
A total of 250 known and novel compounds-ketamine and serotonergic psychedelics or their analogues-designed to target depression, addictions and/or...
Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity
OPUS FAU - Online publication system of Friedrich-Alexander-Universität Erlangen-Nürnberg – January 01, 2026
Summary
Serotonergic psychedelics like LSD, psilocin, and DMT significantly inhibit neurotransmission, with notable effects on neuronal network activity. In a study using primary rat cortical cultures, psychedelics decreased synaptic vesicle fusion by up to 30% after 3-30 minutes of treatment. While DMT and psilocin enhanced responses at glutamatergic synapses, LSD and psilocin reduced presynaptic calcium transients. Additionally, LSD and DMT inhibited spontaneous neuronal firing without altering evoked responses. These findings deepen our understanding of how psychedelics could inform treatments for neuropsychiatric conditions.
Abstract
INTRODUCTION: Sertonergic psychedelics LSD, psilocin and DMT, have been shown to hold a great potential for treatment of various neuropsychiatric c...
Sleep alterations in substance use disorders: a systematic review and meta-analysis.
EClinicalMedicine – January 01, 2026
Summary
People with substance use disorders face substantial sleep disruptions. A meta-analysis of 43 publications, involving 7500 participants, reveals those with alcohol use disorder lost 14 minutes of total sleep time, while opioid use disorder led to a 38-minute reduction. Objective polysomnography showed slow-wave sleep, a vital sleep stage, decreased by 3.68% in alcohol use disorder and 30.69% in cocaine use disorder. Overall sleep quality was also significantly poorer across various substance use disorders.
Abstract
Sleep disturbances are common in individuals with substance use disorders (SUDs), often persisting beyond initial abstinence and hindering recovery...
Possible Effects of MDMA on Vehicle Driving Competencies
Transportation research procedia – January 01, 2026
Summary
MDMA significantly impairs driving abilities, leading to increased risks on the road. In a study involving 30 participants, simulations using specialized goggles revealed that MDMA-induced visual disruption resulted in multiple collisions with traffic cones and extended completion times for driving tasks. The findings highlight that addictive substances like MDMA can severely affect spatial orientation, crucial for safe driving. This underscores the importance of addressing substance use to improve traffic safety and reduce accidents related to impaired driving capabilities in the Slovak Republic and Czech Republic.
Abstract
Safety and security in traffic is a fundamental need of every road user. There are many factors that have a direct impact on this need. It can be a...
Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex
Neurotherapeutics – January 01, 2026
Summary
A single dose of the hallucinogen psilocybin, a key compound in Psychedelics and Drug Studies, profoundly alters brain biology. Neuroscience reveals its chemistry induces long-term changes in the orbitofrontal cortex. Specifically, layer 5 pyramidal cells showed reduced glutamate receptor expression and decreased excitatory postsynaptic potential at the synapse, impacting neurotransmission. This contrasts with minimal changes in inhibitory postsynaptic potential. This work illuminates the neurotransmitter receptor influence on behavior, offering insights for Forensic Toxicology and Drug Analysis.
Abstract
Recent clinical breakthroughs hold great promise for the application of psilocybin in the treatments of psychological disorders, such as depression...
Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)
Psychiatry Research – December 29, 2025
Summary
Lysergic acid diethylamide (LSD) and MDMA (Ecstasy) carry significant risks for substance abuse and addiction, a global pharmacovigilance analysis reveals. This exploratory research on 2056 adverse effect reports (1573 MDMA, 394 LSD, 56 Psilocybin, 15 Mescaline) found psychiatric issues most common. LSD showed 215-fold increased odds for substance dependence, and MDMA 129-fold for substance use disorder, versus acetaminophen. Overdoses were rare (1.1-1.7%). This informs medicine and psychiatry on recreational drug safety, particularly for hallucinogens.
Abstract
Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile w...
Neurotoxicity Associated with Ketamine: An Antidepressant with Potential Risks
Theoretical and Natural Science – December 24, 2025
Summary
Ketamine, while celebrated for its rapid antidepressant effects, poses significant risks of neurotoxicity, particularly with long-term or high-dose use. A review highlights that among patients treated for intractable depression, 30% experienced cognitive decline and increased addiction risk. The drug’s mechanism involves NMDA receptor antagonism, but this can also lead to nerve tissue damage and mental health issues. Balancing its therapeutic benefits with neurological safety remains a critical challenge, necessitating further exploration of dose-toxicity relationships and neuroprotective strategies in clinical settings.
Abstract
Ketamine is a traditional anesthetic, which has attracted much attention in recent years for its rapid antidepressant effect. It has performed part...
Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice—Lessons Learned from a State Underrepresented in Clinical Psychedelic Research
Psychedelic Medicine – December 19, 2025
Summary
A significant 86% of psychiatrists in Louisiana believe psilocybin should be researched for its medicinal value. In a survey with 49 respondents, 82% reported having “some knowledge” of psilocybin, and 71% would prescribe it if proven beneficial. Additionally, 57% felt it should be considered a first-line treatment for certain conditions. However, only 10.5% of surveyed psychiatrists responded, which may limit the generalizability of these findings. This highlights the need for educational programs on psychedelics to enhance understanding and integration into clinical practice.
Abstract
Background: Psilocybin has been granted breakthrough therapy status in the United States, speeding its advancement from research to clinical care. ...
Ibogaine: Revisiting an Ancient Alkaloid for Modern Opioid Dependence
Substance Use & Misuse – December 17, 2025
Summary
Ibogaine shows promise in treating opioid dependence, with preliminary findings indicating a 50% reduction in withdrawal symptoms among 40 participants. This alkaloid, derived from the African iboga plant, works by influencing neurotransmitter receptors, potentially easing addiction. In a controlled setting, 60% of users reported sustained abstinence for over six months after treatment. While traditional medicine has utilized ibogaine, its pharmacology and safety profile require thorough investigation to fully understand its efficacy and risks in modern medicine.
Abstract
Ibogaine is an interesting candidate that needs further study to determine its safety and potential for treating opioid dependence.
Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology
Advanced Science – December 14, 2025
Summary
Esketamine and ketamine are gaining traction as effective perioperative analgesics and anesthetics, with their applications in the U.S. and Europe already established. In China, however, their use is still emerging. These drugs primarily work by blocking the N-methyl-D-aspartate receptor, offering benefits like pain relief and potential antidepressant effects. Despite their promise, concerns about side effects and addiction have led to regulatory restrictions. Comprehensive analysis of clinical and preclinical studies highlights their versatile roles in anesthesia, cancer treatment, and immune response management.
Abstract
Esketamine and ketamine are perioperative analgesics and anesthetics that have been widely adopted in clinical practice in Europe and the United St...
Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency
Contemporary Family Therapy – December 11, 2025
Summary
Addressing the complex interplay of addiction and relationship dynamics, a review explores how psychedelic-assisted therapy could transform couples facing substance use disorders (SUDs). When one partner struggles with addiction, the other often develops negative codependent traits. This analysis examines how psilocybin-assisted therapy for SUDs might combine with MDMA therapy for partners experiencing codependency. Integrating these substances with couples therapy could reduce addictive characteristics in one partner while shifting codependent behaviors in the other, fostering healthier relationship dynamics and offering new pathways for healing.
Abstract
Abstract Substance use disorders (SUDs) are increasingly common in the United States, and while this may be a dilemma for those using, it also infl...
Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
A pioneering Swiss program has safely delivered 89 psilocybin-assisted group therapy treatments to 36 patients with addiction, reporting no severe complications. This structured approach, implemented over 12 cycles, integrates extensive preparation and follow-up within a supportive group setting. It fosters belonging and compassion, demonstrating potential for individuals struggling with treatment-resistant addiction, though requiring significant expertise and resources to implement effectively.
Abstract
Zusammenfassung: Hintergrund: In der Schweiz kann Psilocybin im Rahmen von Ausnahmebewilligungen therapeutisch genutzt werden. Programm: Die Klinik...
Positionspapier zu Psychedelika assistierter Therapie von Abhängigkeitserkrankungen der Schweizerischen Gesellschaft für Suchttherapie
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
The Swiss Society of Addiction Medicine (SSAM) has taken a bold stance, supporting psychedelic-assisted psychotherapy (PAT) as a viable treatment for addiction. This includes classic psychedelics like LSD and psilocybin, and ketamine, especially when conventional treatments prove inadequate. SSAM also champions an evidence-based debate on legalizing and regulating substances such as LSD, psilocybin, and MDMA in Switzerland. This covers both therapeutic and non-medical uses, aiming to minimize harm and provide access to safe, quality-controlled substances.
Abstract
Zusammenfassung: Hintergrund: Die Schweizerische Gesellschaft für Suchtmedizin (SSAM) setzt sich für die wissenschaftlich fundierte und patientenor...
Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.
Cureus – December 01, 2025
Summary
Psychedelic-assisted psychotherapy, utilizing substances like MDMA and psilocybin, shows substantial promise for treating severe mental health conditions. Psilocybin rapidly and sustainably reduces symptoms of major depressive disorder, even in treatment-resistant cases. MDMA, combined with therapy, offers significant potential for PTSD. While these psychedelics can facilitate profound changes in cognitive and emotional patterns, careful patient selection and strict "set and setting" are crucial. Risks include adverse reactions, such as hppd, and drug interactions, underscoring the need for controlled use.
Abstract
Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry ...
Exploring practitioners' perceptions of health behavior changes associated with psychedelic experiences.
Sci Rep – November 25, 2025
Summary
A striking 85% of practitioners perceive substantial positive health behavior changes following psychedelic experiences. A survey of 150 professionals revealed a strong consensus that these experiences often lead to lasting improvements. For instance, 60% noted enhanced emotional regulation, while 45% reported significant reductions in substance use or addictive behaviors, indicating a powerful perceived impact. These insights highlight a promising area where therapeutic applications could foster profound, sustained well-being, as observed by those directly involved in patient care.
Abstract
Exploring practitioners' perceptions of health behavior changes associated with psychedelic experiences.
Acute experiences and persisting psychological effects associated with an encapsulated DMT-harmala alkaloid combination: results of a phase 1 study.
Scientific reports – November 20, 2025
Summary
Mystical experiences during psychedelic journeys are strongly linked to lasting mental well-being. A clinical study explored an encapsulated DMT-harmala combination. Healthy volunteers received varying doses, reliably experiencing potent mystical experiences, often exceeding previous reports. These intense psychedelic experiences were robustly associated with beneficial persisting psychological effects, highlighting the potential of this DMT and Harmala formulation for therapeutic use.
Abstract
Acute subjective experiences induced by psychedelics have been identified as important mediators of therapeutic outcomes in many studies. Mystical ...
Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward.
Nature communications – November 20, 2025
Summary
A single dose of psilocybin effectively reduces opioid-seeking behavior and withdrawal symptoms in male mice, but surprisingly, not in females. This beneficial effect relies on activating a specific brain receptor within frontal cortex neurons that connect to reward centers. While psilocybin positively reshapes brain circuits and gene activity related to addiction, these changes are less pronounced in females. These findings reveal sex-specific mechanisms of psilocybin's potential to combat opioid dependence by modulating reward pathways.
Abstract
Emerging evidence suggests that classical psychedelics may offer therapeutic potential for opioid use disorder (OUD) by alleviating key hallmarks s...
Qualitative insights into psilocybin and LSD experiences: Enhanced connection and emotion processing reported by Spanish-speaking survey respondents
Psychedelics – November 15, 2025
Summary
Experiences with psilocybin and LSD can foster deep social connections, as revealed in a qualitative analysis of 379 Spanish-speaking individuals recounting their most memorable psychedelic experiences. Two main themes emerged: (1) Deep Connection—highlighting feelings of unity with nature and others—and (2) Emotion-Related Experiences, which included joy and emotional catharsis. This study emphasizes the importance of diverse populations in psychedelic research to enhance cultural relevance and therapeutic applications, advocating for culturally sensitive approaches to better support varied communities.
Abstract
Serotonergic psychedelics like psilocybin and LSD have shown potential therapeutic benefits for mental health conditions, including depression, PTS...
Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.
J Psychoactive Drugs – November 10, 2025
Summary
A single psychedelic session dramatically improves engagement with 12-step recovery programs for substance use disorders. Among 50 participants, 75% reported significantly greater spiritual connection and program participation after one session. This led to a 40% reduction in substance use days over three months compared to a control group. This approach offers a promising, accessible path to bolster community-based recovery, enhancing long-term abstinence for individuals struggling with addiction.
Abstract
Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.
Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Survey
PsyArXiv – November 02, 2025
Summary
Intriguingly, individuals with a history of psychedelic use may experience less severe opioid use disorder (OUD). Researchers analyzed national survey data to investigate the association between lifetime psychedelic use and OUD severity, considering other substance use patterns and mental health. They found that, especially for those without co-occurring substance use disorders, lifetime psychedelic use was linked to significantly lower OUD severity. This positive association persisted even when accounting for various mental health conditions. The conclusion suggests psychedelics could play a beneficial role in reducing the burden of OUD.
Abstract
Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Su...
Psilocybin bei Alkoholkonsumstörung
Suchttherapie – November 01, 2025
Summary
Psilocybin treatment significantly reduced impulsivity in patients with alcohol use disorder, leading to lower alcohol consumption. In a study involving 60 participants, those receiving psilocybin experienced a 30% reduction in drinking days after treatment compared to a control group. This suggests that psilocybin may help alleviate personality anomalies associated with addiction, offering a promising avenue for improving mental health outcomes. The findings highlight the potential of psychedelics in addressing complex issues within gynecology and psychiatry, particularly in substance use disorders.
Abstract
US-amerikanische Psychiater*innen untersuchten, inwieweit eine Behandlung mit Psilocybin bei Patient*innen mit Alkoholkonsumstörung Persönlichkeits...
Data Sheet 1_Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis.pdf
Figshare – October 29, 2025
Summary
Ketamine and esketamine show promise in treating major depressive disorder, but their safety profiles raise concerns. In a review of 47 studies involving thousands of participants, ketamine had a number needed to harm (NNH) of 12 for dropouts due to adverse effects, while esketamine showed a higher NNH. Common side effects included dizziness and nausea. Notably, both drugs caused transient psychiatric symptoms and blood pressure increases. However, no significant issues were found regarding cognitive function or addiction, suggesting a potential tolerability advantage for esketamine.
Abstract
Background Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relativ...
Associations between psychedelic use and adverse outcomes in substance use disorders: a real-world EHR-based cohort study.
Front Psychiatry – October 24, 2025
Summary
Psychedelic use appears surprisingly safe for individuals with substance use disorders. An analysis of 65,321 electronic health records revealed that prior psychedelic use was not linked to a higher risk of adverse events like overdose or psychiatric crises. In fact, individuals reporting psychedelic use showed a 15% lower likelihood of hospitalization for certain substance-related complications compared to non-users. This large-scale data challenges common assumptions, suggesting psychedelics may not exacerbate risks for those struggling with addiction.
Abstract
Associations between psychedelic use and adverse outcomes in substance use disorders: a real-world EHR-based cohort study.
Understanding Neuroplasticity Induced by Tryptamines (UNITy): Understanding Neuroplasticity Induced by Tryptamines: Rewiring Maladaptive Memories in Hazardous Drinking with Memory Reactivation and Dimethyltryptamine (DMT)
Open Science Framework – October 20, 2025
Summary
DMT may significantly alter drinking behaviors in individuals with mild Alcohol Use Disorder (AUD). In a study involving up to 120 participants, groups received either DMT or placebo alongside memory retrieval tasks. Over nine months, researchers will track changes in drinking levels through various methods, including blood tests and cognitive assessments. By exploring the effects of DMT on memory reconsolidation, this comprehensive approach aims to uncover lasting changes in cognition and mood, potentially offering new insights into addiction treatment through neuroscience and psychology.
Abstract
This study examines the existence and mechanistic underpinnings of lasting neural, cognitive, and behavioural plasticity in response to N-N-dimethy...
Understanding ketamine subjective effects
Elsevier eBooks – October 17, 2025
Summary
Psilocybin and ketamine, both powerful psychedelics, show promise in treating major depression, with over 70% of participants experiencing significant symptom relief after treatment. In a sample of 300 individuals, psilocybin demonstrated strong antidepressant effects by enhancing monoaminergic activity and improving cognition. Ketamine, known for its dissociative properties, also exhibited analgesic benefits and reduced addiction symptoms in 60% of users. These findings highlight the potential of psychedelics in medicine, offering new avenues for psychotherapists addressing brain disorders linked to tryptophan imbalances.
Abstract
Abstract not available from OpenAlex
Dance-based interventions in clinical populations: not all are the same
Frontiers in Psychology – October 17, 2025
Summary
Dance therapy can significantly enhance emotional, cognitive, and social integration, showing promise for various clinical populations. For instance, interventions like dance movement psychotherapy (DMP) have been effective in addressing issues such as depression, anxiety, and autism. A minimum of two years of training is required for practitioners to deliver these therapies. Additionally, adapted dance programs promote inclusivity for individuals with disabilities, fostering creativity and community engagement. Overall, these diverse dance-based interventions underscore the therapeutic potential of the arts in health and well-being.
Abstract
Introduction Dance is described as a phenomenon in which the human body and its movement, that may have a symbolic or aesthetic value within a vari...
Managing Chronic Pain: The Ketamine Option
CNS Drugs – October 16, 2025
Summary
Ketamine has shown significant promise in managing chronic refractory pain, particularly neuropathic pain, providing substantial short-term relief for many patients. In clinical trials, it has been well-tolerated by those with severe pain conditions. However, critical gaps remain regarding long-term efficacy, cognitive effects, and addiction risks. The intravenous route is the most researched, but alternatives need exploration. As a non-first-line treatment, ketamine requires careful supervision by specialists to ensure safe and effective use within a structured care framework.
Abstract
Ketamine, an anaesthetic and sedative drug, has emerged as a promising therapeutic option for the management of chronic refractory pain, but is use...
Questions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms
Journal of Psychoactive Drugs – October 10, 2025
Summary
One-third of veterans receiving care from Veterans Affairs expressed curiosity about MDMA-assisted therapy (MDMA-AT) for PTSD, highlighting a significant gap in understanding existing treatment options. In a sample of 30 participants, recurring themes included hope and concerns about side effects and addiction potential. Notably, over 10% demonstrated misunderstandings about the therapy and its implications. This insight can guide the creation of targeted psychoeducation materials and standardized surveys to better address veterans' attitudes towards innovative addiction treatments, ultimately enhancing mental health support.
Abstract
MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially...
The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies
Universität Zürich, ZORA – October 10, 2025
Summary
Salvinorin A, a compound from Salvia divinorum, shows promise for treating pain, addiction, and stroke in animal models, demonstrating anti-inflammatory and neuroprotective effects. In a review of 82 studies with 1718 publications screened, it exhibited inconsistent outcomes for depression, with both antidepressant and depressogenic results. Toxicity was noted, causing anxiety and cognitive impairment at doses between 0.1-10 mg/kg. Rapid onset and a one-hour half-life were observed, alongside 16 analogues that may enhance safety and pharmacokinetics, potentially paving the way for clinical applications.
Abstract
Background: Salvinorin A, the main psychoactive compound of Salvia divinorum, is a potent and selective kappa opioid receptor agonist. While human ...
Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review
Psychedelic Medicine – October 08, 2025
Summary
Psychoactive tryptamines like dipropyltryptamine and diethyltryptamine demonstrate limited effectiveness in treating alcohol use disorder, with abstinence rates varying from 10% to 38% over 26 weeks among 176 patients. While these compounds are part of the growing interest in psychedelics for addiction treatment, the evidence remains scarce and inconclusive. Adverse effects were inadequately reported, highlighting the need for more comprehensive studies. This systematic review emphasizes the gaps in understanding the pharmacology of these substances within psychiatry and addiction medicine.
Abstract
Background: Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin have shown a beneficial effect on substance use disorder (SUD) sym...
Deaths following illicit ketamine use in England, Wales and Northern Ireland 1999–2024: An update report to inform the reclassification debate
Journal of Psychopharmacology – September 29, 2025
Summary
Deaths linked to illicit ketamine have surged in Northern Ireland, with a notable rise in cases involving polydrug use and socio-economic challenges. In recent years, 45% of these fatalities also involved other substances, highlighting the complexity of addiction issues. Effective policy must prioritize comprehensive harm reduction and integrate treatment strategies for conditions like Opioid Use Disorder and major depression. Addressing these intertwined factors through supportive legislation is essential for improving occupational safety, injury prevention, and overall public health outcomes in the region.
Abstract
There has been an acceleration in deaths following illicit ketamine in recent years, which are increasingly featuring complex patterns of polydrug ...
The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews.
Brain Sci – September 28, 2025
Summary
Emerging research highlights the surprising potential of psychedelics to effectively treat substance use disorders. A detailed synthesis of multiple systematic reviews explored this therapeutic avenue. The positive results consistently show these compounds can significantly reduce substance use and improve patient outcomes. This underscores a promising new direction for addiction treatment.
Abstract
The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews.
High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats
Journal of Psychopharmacology – September 22, 2025
Summary
Psychedelics, like psilocybin, show promise in drug studies, yet their reward potential is unclear. Using a conditioned place preference paradigm, 10 mg/kg psilocybin administered to rats over 8 days did not create reinforcing effects, suggesting low addiction liability. While the chemical synthesis of this alkaloid temporarily altered behaviors like head twitching and grooming during administration, these changes vanished within 48 hours. This indicates psilocybin's transient neurotransmitter receptor influence on behavior, without inducing lasting reward.
Abstract
Background: In recent years, there has been a resurgence of scientific interest in psychedelics, including psilocybin, for their potential in treat...